Medix Biochemica has announced the launch of its refreshed and expanding brand to reflect both the exciting improvements to its offering as a result of recent acquisitions and its ongoing commitment to the in vitro diagnostics (IVD) industry.
In past couple of years Medix Biochemica has acquired several companies, each with their own expertise across the IVD market. In 2019, Lee Biosolutions was acquired, followed by EastCoast Bio and Biostride in 2020, Diaclone just last year and, most recently, myPOLS Biotec GmbH, which will, company believes, strengthen its existing molecular diagnostics division, MedixMDx.
This integration has helped Medix Biochemica broaden its portfolio to over 5,000 products in categories such as molecular reagents, enzymes, biospecimens and immunoreagents. An expanded portfolio and streamlined experience has been a recurring request in recent key customer surveys, the company said.
The company announces that from now on customers will be able to find whatever they need in one place: the Medix Biochemica website. The new website will be the go-to place for customers to discover just how much Medix Biochemica can do for them. Whether it’s a streamlined product experience or a specific service such as antibody, DNA or RNA polymerase engineering, customers will be able to find out more and contact the company directly to discuss their needs.